Low-dose recombinant factor VIII lowered bleeding rates in Chinese children with hemophilia, and the earlier the preventive treatment began, the more effective it was in minimizing bleeding episodes, according to a new study. The research, “The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A:…
More than 1,300 people who have been affected by acquired immune deficiency syndrome (AIDS) gathered at the National AIDS Memorial in San Francisco on Dec. 1 to commemorate World AIDS Day. During two days of events, family and friends paid tributes to those lost to the disease, while inspiring remembrance…
Two presentations at the 2016 American Society of Hematology Annual Meeting (ASH) highlight ongoing treatment advances for hemophilia B. The data suggest that life with hemophilia could soon become easier to manage. Long-acting replacement therapy The ASH meeting, held in San Diego on Dec. 3-6, was a platform for CSL Behring to…
Researchers have successfully applied a potential gene therapy for hemophilia B based on the genome editing properties of the CRISPR/Cas9 system. The results of this study using mice were presented recently at the 58th Annual American Society of Hematology Meeting and Exposition in San Diego, Calif. Hemophilia B is a disease…
Researchers have developed a biodegradable capsule to deliver a protein missing in patients with hemophilia B, according to a new study published in the International Journal of Pharmaceutics. If it proves to be successful, this capsule may provide a cheaper and less painful option to injections or infusions. The…
A combination of drugs acting on different points of the pain pathway may be beneficial in reducing joint pain in people with hemophilia, according to a review article published in the journal Blood Coagulation and Fibrinolysis.
Biogen recently hired two more executive management team members for Bioverativ, a Biogen spin-off company that is expected to be up and running in early 2017. Bioverativ will focus on the discovery, research, development, and commercialization of new treatments for hemophilia and other blood disorders. Rogerio Vivaldi, MD, is Bioverativ’s new executive…
Two clinical trials launching in December will use Octapharma USA’s Wilate, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection, in patients with hemophilia A. Hemophilia A is an X-linked hereditary bleeding disorder that results from either reduced or absent levels of…
NuFACTORÂ is accepting applications for the 2017 Annual Eric Dostie Memorial College Scholarship. NuFACTOR is a specialty pharmacy of FFF Enterprises, a distributor of plasma products, vaccines and biosimilars, among others. NuFACTOR specializes in the treatment of chronic conditions in several areas of medicine, including blood disorders and…
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Afstyla (lonoctocog alfa) for the treatment and prevention of bleeding in adults and children with hemophilia A. Developed by CSL Behring, Afstyla is a single-chain recombinant human factor VIII…
Get regular updates to your inbox.